九强生物 reported revenue of ¥0.68B for the period ended 2026-06-30, +1.5% year on year. Net income was ¥0.21B, a 31.0% net margin on a 80.9% gross margin. The largest revenue line is 体外检测试剂 at 96% of the total. Free cash flow for the period was ¥0.15B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.68B | +1.5% |
| Gross profit | ¥0.55B | — |
| Operating income | ¥0.24B | — |
| Net income | ¥0.21B | +19.7% |
| Gross margin | 80.9% | Net margin 31.0% |
| Revenue Q/Q | +2.7% | — |
| Segment | Revenue | Share |
|---|---|---|
| 体外检测试剂 | ¥0.65B | 95.8% |
| 体外检测仪器 | ¥0.01B | 2.1% |
| 其他(补充) | ¥0.01B | 1.2% |
| 检验服务及实验辅助业务 | ¥0.00B | 0.6% |
| 仪器租赁收入 | ¥0.00B | 0.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.13B | 19.1% |
| R&D | ¥0.08B | 12.2% |
| SG&A | ¥0.19B | 27.6% |
| Tax & other | ¥0.03B | 4.5% |
| Item | Amount |
|---|---|
| Total assets | ¥4.87B |
| Total liabilities | ¥1.29B |
| Shareholders' equity | ¥3.58B |
| Equity / assets | 73.5% |
| Operating cash flow | ¥0.15B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.15B |
| Cash conversion (OCF / net income) | 117% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
凯发电气 ・ 道氏技术 ・ 正业科技 ・ 金盾股份 ・ 迦南科技 ・ 中光防雷 ・ 伊之密 ・ 苏试试验 ・ 南华仪器 ・ ST浩丰 ・ 五洋自控 ・ 力星股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies